AU2001258489A1 - Novel vitronectin receptor antagonists - Google Patents

Novel vitronectin receptor antagonists

Info

Publication number
AU2001258489A1
AU2001258489A1 AU2001258489A AU5848901A AU2001258489A1 AU 2001258489 A1 AU2001258489 A1 AU 2001258489A1 AU 2001258489 A AU2001258489 A AU 2001258489A AU 5848901 A AU5848901 A AU 5848901A AU 2001258489 A1 AU2001258489 A1 AU 2001258489A1
Authority
AU
Australia
Prior art keywords
vitronectin receptor
receptor antagonists
novel
formula
novel vitronectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258489A
Other languages
English (en)
Inventor
Jacques Demassey
Jean-Francois Gourvest
Jean-Michel Lefrancois
Jean-Marie Ruxer
John Bernard Weston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001258489A1 publication Critical patent/AU2001258489A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001258489A 2000-05-09 2001-05-04 Novel vitronectin receptor antagonists Abandoned AU2001258489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0005859A FR2808798A1 (fr) 2000-05-09 2000-05-09 Nouveaux derives antagonistes du recepteur de la vitronectine
FR0005859 2000-05-09
PCT/FR2001/001357 WO2001085729A1 (fr) 2000-05-09 2001-05-04 Nouveaux derives antagonistes du recepteur de la vitronectine

Publications (1)

Publication Number Publication Date
AU2001258489A1 true AU2001258489A1 (en) 2001-11-20

Family

ID=8850000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258489A Abandoned AU2001258489A1 (en) 2000-05-09 2001-05-04 Novel vitronectin receptor antagonists

Country Status (12)

Country Link
US (1) US6838453B2 (OSRAM)
EP (1) EP1282621B1 (OSRAM)
JP (1) JP5143989B2 (OSRAM)
AT (1) ATE304012T1 (OSRAM)
AU (1) AU2001258489A1 (OSRAM)
CA (1) CA2408293A1 (OSRAM)
DE (1) DE60113248T2 (OSRAM)
ES (1) ES2249431T3 (OSRAM)
FR (1) FR2808798A1 (OSRAM)
IL (1) IL152613A0 (OSRAM)
MX (1) MXPA02011043A (OSRAM)
WO (1) WO2001085729A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3332679B2 (ja) 1995-08-08 2002-10-07 昭和電工株式会社 押継ぎ押出用ダイス
PL371841A1 (pl) 2004-12-20 2006-06-26 ADAMED Sp.z o.o. Nowe związki pochodne kwasu 3-fenylopropionowego
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
MX2019000043A (es) 2016-07-05 2019-07-04 Univ Rockefeller Antagonistas de integrina de tetrahidronaftiridinpentanamida.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
JP2002501054A (ja) * 1998-01-23 2002-01-15 アヴェンティス ファルマ ドイチェラント ゲーエムベーハー 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
DZ2741A1 (fr) * 1998-03-10 2003-09-08 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine procédé pour leur préparation et compositions.
ATE253061T1 (de) * 1998-06-29 2003-11-15 Iaf Biochem Int Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
US6630488B1 (en) * 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
GB9821061D0 (en) * 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
ES2249431T3 (es) 2006-04-01
DE60113248D1 (de) 2005-10-13
WO2001085729A1 (fr) 2001-11-15
JP5143989B2 (ja) 2013-02-13
JP2003532732A (ja) 2003-11-05
US6838453B2 (en) 2005-01-04
US20040225111A1 (en) 2004-11-11
EP1282621A1 (fr) 2003-02-12
FR2808798A1 (fr) 2001-11-16
MXPA02011043A (es) 2003-03-10
CA2408293A1 (fr) 2001-11-15
EP1282621B1 (fr) 2005-09-07
IL152613A0 (en) 2003-06-24
ATE304012T1 (de) 2005-09-15
DE60113248T2 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
ATE316083T1 (de) Adamantanderivate
SE9904505D0 (sv) Novel compounds
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
SE9901875D0 (sv) Novel compounds
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MY138734A (en) Casr antagonist
DE602004011966D1 (en) Heterocyclylverbindungen
MXPA04003730A (es) Derivados del 3-azabiciclo[3.1.0]hexano.
MEP55308A (en) New pharmaceutical compositions containing flibanserin polymorph a
WO2003053945A3 (en) Urea derivatives and their use as vanilloid receptor antagonists
GB0109122D0 (en) Novel compounds
TW200639156A (en) New compounds
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
IL152613A0 (en) Novel vitronectin receptor antagonists
MXPA05011841A (es) Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1.
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.
SE0202693D0 (sv) Compounds